Table 2—

Glycemic parameters at the end of each treatment period

Glycemic parameter     Treatment sequencenBaselineTreatment
Difference (CSII − MDI)P
nCSIInMDI
Mean fructosamine (μmol/l)
    CSII to MDI50351 ± 4448352 ± 4649360 ± 49
    MDI to CSII49345 ± 4850334 ± 4848349 ± 50
    Combined subjectsNA98*343 ± 4797355 ± 50−11.8 [−13.4 to −4.63]0.0001
Mean AUC glucose ≥80 mg/dl (mb · h · dl−1)
    CSII to MDINA371,150 ± 758341,605 ± 1018
    MDI to CSIINA331,403 ± 713371,718 ± 1,069
    Combined subjectsNA701,270 ± 742711,664 ± 1039−394 [−654 to −196]0.0005
Mean AUC glucose ≥140 mg/dl (mg · h · dl−1)
    CSII to MDINA37381 ± 39734774 ± 721
    MDI to CSIINA33557 ± 49637779 ± 778
    Combined subjectsNA70464 ± 45271777 ± 746−313 [−489 to −150]0.0004
Daily insulin dose (units)§
    CSII to MDI4542.3 ± 17.95042.1 ± 19.24646.0 ± 18.2
    MDI to CSII5041.6 ± 16.14839.6 ± 17.55046.2 ± 20.5
    Combined subjects9541.9 ± 16.99840.9 ± 18.49646.1 ± 19.40.08
  • Data are means ± SD or difference [95% CI].

  • *

    * Numbers of subjects are greater than those who completed the trial because fructosamine was determined at an end- of-study visit; the last observation carried forward approach was used for fructosamine;

  • statistical inference was made for combined values only; treatment, sequence, and center were included as fixed effect, subject as random effect in the model;

  • AUC glucose was based on the first 24 h of CGMS monitoring; §treatment insulin dose values were measured after the 1-week dose adjustment period for each treatment period.